SCHEMBL15416384

SCHEMBL15416384

CC1(C)OB(c2ccc(NC(=O)Cc3ccc(F)cc3)cc2)OC1(C)C

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.64
SMN1; SMN2 Q16637 2/20 0.60
CXCR2 P25025 1/20 0.56
MAPK1 P28482 2/20 0.55
MEN1 O00255 2/20 0.55
KMT2A Q03164 2/20 0.55
LPL P06858 1/20 0.52
LIPG Q9Y5X9 1/20 0.52
CA1 P00915 3/20 0.52
CA2 P00918 3/20 0.52
CA9 Q16790 3/20 0.52
CA12 O43570 1/20 0.52
TSHR P16473 1/20 0.51
ALDH1A1 P00352 3/20 0.49
KDM4E B2RXH2 1/20 0.49
HPGD P15428 1/20 0.49
MAPT P10636 1/20 0.46
POLB P06746 1/20 0.45
RORC P51449 1/20 0.45
HDAC1 Q13547 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6862380 0.87 EPHX2 (0.58) GAASMN1; SMN2MEN1KMT2ALPL
SCHEMBL257808 0.87 EPHX2 (0.58) GAASMN1; SMN2MEN1KMT2ALPL
SCHEMBL422455 0.84 LPL (0.61) SMN1; SMN2CXCR2MAPK1MEN1KMT2A
SCHEMBL14746483 0.83 RORC (0.60) CA1CA2CA9RORC
SCHEMBL28523926 0.83 GAA (0.55) GAASMN1; SMN2CXCR2MAPK1MEN1
SCHEMBL22267274 0.81 CXCR2 (0.61) GAACXCR2KMT2ALPLLIPG
SCHEMBL22267423 0.81 MEN1 (0.59) SMN1; SMN2CXCR2MEN1KMT2ALPL
SCHEMBL28558552 0.80 CA1 (0.69) CXCR2MEN1KMT2ALPLLIPG
SCHEMBL14267207 0.80 HDAC1 (0.52) CXCR2LPLLIPGCA1CA2
SCHEMBL17316652 0.79 CACNA1I (0.65) SMN1; SMN2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3008062-B1 PRODRUG DERIVATIVES OF SUBSTITUTED TRIAZOLOPYRIDINES Bayer Pharma AG (DE) 2017-04-05 EP disclosed
US-9388177-B2 Method for preparing substituted triazolopyridines BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-07-12 US disclosed
US-9388177-B2 Method for preparing substituted triazolopyridines BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-07-12 US disclosed
US-20150148542-A1 METHOD FOR PREPARING SUBSTITUTED TRIAZOLOPYRIDINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2015-05-28 US disclosed
US-20150148542-A1 METHOD FOR PREPARING SUBSTITUTED TRIAZOLOPYRIDINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2015-05-28 US disclosed
EP-2872506-A1 METHOD FOR PREPARING SUBSTITUTED TRIAZOLOPYRIDINES Bayer Pharma Aktiengesellschaft (DE) 2015-05-20 EP disclosed
WO-2014009219-A1 METHOD FOR PREPARING SUBSTITUTED TRIAZOLOPYRIDINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2014-01-16 WO disclosed
WO-2014009219-A1 METHOD FOR PREPARING SUBSTITUTED TRIAZOLOPYRIDINES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2014-01-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150148542-A1 METHOD FOR PREPARING SUBSTITUTED TRIAZOLOPYRIDINES QDPR, CYP3A5, CYP3A7 GAA 328/4885SMN1; SMN2 2443/4885CXCR2 2332/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.